Wockhardt Posts Rs 780 Million Profit In September Quarter, Revenue At Rs 7.82 Billion

Strong Quarter Backed By Global Pharma Momentum  
Wockhardt Ltd has delivered a robust financial performance for Q2 FY2025–26, with consolidated revenue from operations reaching Rs 7.82 billion and net profit standing at Rs 780 million. The company’s growth was driven by increased demand for its specialty formulations and continued traction in regulated markets such as the US, UK, and emerging economies.

Operational efficiency and portfolio rationalization contributed to improved margins, while strategic investments in R&D and biosimilars are expected to support long-term growth. Wockhardt’s focus on high-value products and global partnerships continues to reinforce its competitive position in the pharmaceutical sector.

Major Takeaways  

• Consolidated revenue from operations: Rs 7.82 billion  
• Net profit for Q2 FY2025–26: Rs 780 million  
• Growth led by specialty drugs and international market expansion  
• Operational cost controls supported margin improvement  
• Continued investment in biosimilars and R&D pipeline

Sources: Reuters, Business Standard, Moneycontrol, Wockhardt Investor Updates, NSE India